Molecular pathways and targeted therapy in cholangiocarcinoma.
Clin Adv Hematol Oncol
; 17(11): 630-637, 2019 Nov.
Article
en En
| MEDLINE
| ID: mdl-31851165
ABSTRACT
Cholangiocarcinoma (CCA) encompasses a rare group of malignancies arising from epithelial cells lining the biliary tree that connects the liver and gallbladder to the small intestine. Most patients present with advanced incurable disease that has a poor prognosis, and standard treatment options remain limited. Effective nontoxic treatment options for advanced CCA are needed. Fibroblast growth factors (FGFs) and their fibroblast growth factor receptor (FGFR) pathways are crucial to cellular proliferation, cellular survival, and differentiation of many malignancies, but are especially relevant in CCA. The targeting of FGF/FGFR has become the most promising approach to treating patients with advanced/metastatic CCA. Here we review CCA, and discuss the promise of FGFR-directed therapy in advanced CCA.
Buscar en Google
Colección:
01-internacional
Asunto principal:
Neoplasias de los Conductos Biliares
/
Receptores de Factores de Crecimiento de Fibroblastos
/
Colangiocarcinoma
/
Terapia Molecular Dirigida
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Clin Adv Hematol Oncol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
Año:
2019
Tipo del documento:
Article